Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes

Pharmacogenetics and Genomics

Volumn 21, Issue 1, 2011, Pages 26-34

  Teichert, Martina ^a,c   Eijgelsheim, Mark ^a   Uitterlinden, Andre G ^a   Buhre, Peter N ^b   Hofman, Albert ^a   De Smet, Peter A G M ^c,d   Visser, Loes E ^a   Stricker, Bruno H Ch ^a,d,e  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b STAR Medical Diagnostic Center   (Netherlands)

^c Inspectorate for Health Care   (Netherlands)

^d Inspectorate for Health Care   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

anticoagulation; CYP2C9; CYP4F2; dosage; genome wide association studies; pharmacogenetics; phenprocoumon; VKORC1

Indexed keywords

APOLIPOPROTEIN E; CYTOCHROME; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; CYTOCHROME P450 4F2; MEMBRANE PROTEIN; PHENPROCOUMON; SYNTAXIN 4A; UNCLASSIFIED DRUG; VITAMIN K EPOXIDE REDUCTASE COMPLEX SUBUNIT 1; VITAMIN K GROUP;

AGED; ALLELE; ARTICLE; DNA POLYMORPHISM; DOSE RESPONSE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 78650680251     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32834154fb     Document Type: Article

References (47)

1. Hirsh J, Bauer K, Donati M, Gould M, Samama M, Weitz J, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest 2008; 133:141S-159S (Pubitemid 351892966)
2. Van der Hooft C, Dieleman JP, Siemes C, Aarnoudse ALHJ, Verhamme KC, Stricker BHC, et al. Adverse drug reaction-related hospitalisations: a population-based cohort study. Pharmacoepidemiol Drug Safety 2008; 17:365-371
3. Leendertse A, Egberts A, Stoker L, Bemt van der P. Frequency of and risk factors for preventable medication-related hospital admissions in the Netherlands. Arch Intern Med 2008; 168:1890-1896
4. Teichert M, Van Schaik R, Hofman A, Uitterlinden AG, De Smet P, Stricker B, et al. Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period. Clin Pharmacol Ther 2009; 85:379-386
5. D'Andrea G, D'Ambrosio RL, Di Perna P, Chetta M, Santacroce R, Brancaccio V, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 2005; 105:645-649
6. Geisen C, Watzka M, Sittinger K, Steffens M, Daugela L, Seifried E, et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost 2005; 94:773-779
7. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 2005; 106:2329-2333
8. Aquilante CL, Langaee TY, Lopez LM, Yarandi HN, Tromberg JS, Mohuczy D, et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharm Therap 2006; 79:291-302
9. Carlquist JF, Horne B, Muhlestein J, Lappé D, Whiting B, Kolek MC, et al. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. J Thromb Thrombolysis 2006; 22:191-197
10. Oldenburg J BC, Fregin A, Geisen C, Müller-Reible C, Watzka M. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles. Thromb Haemost 2007; 98:570-578
11. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, Wadelius C, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 2007; 121:23-34
12. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS 2008; 5:e100433
13. Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008; 112:1022-1027
14. Teichert M, Eijgelsheim M, Rivadeneira F, Uitterlinden AG, Van Schaik RHN, Hofman A, et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Gen 2009; 18:3758-3768
15. Visser LE, Van Vliet M, Van Schaik RHN, Kasbergen AAH, De Smet PA, Vulto AG, et al. The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. Pharmacogenetics 2004; 14:27-33
16. Schalekamp T, Oosterhof M, Van Meegen E, Van Der Meer FJM, Conemans J, Hermans M, et al. Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clin Pharmacol Ther 2004; 76:409-417
17. Kirchheiner J, Uver M, Walter E, Kammerer B, Kahlich R, Meisel C. Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. Pharmacogenetics 2004; 14:19-26 (Pubitemid 38183958)
18. Ufer M, Kammerer B, Kahlich R, Kirchheiner J, Yasar U, Brockmöller J, Rane A. Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. Xenobiotica 2004; 34:847-859
19. Werner D, Werner U, Wuerfel A, Grosch A, Lestin H, Eschenhagen T, et al. Pharmacogenetic characteristics of patients with complicated phenprocoumon dosing. Eur J Clin Pharmacol 2009; 65:783-788
20. Hummers-Pradier E, Hess S, Aham I, Papke T, Pieske B, Kochen M. Determination of bleeding risk using genetic markers in patients taking phenprocoumon. Eur J Clin Pharmacol 2003; 59:213-219
21. Reitsma PH, Van der Heijden JF, Groot AP, Rosendaal FR, Buller HR. A C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk. PLoS Med 2005; 2:e312
22. Schalekamp T, Brassé BP, Roijers JFM, Van Meegen E, Van der Meer FJM, Van Wijk EM, et al. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther 2006; 81:185-193
23. Qazim B, Stöllberger C, Krugluger W, Dossenbach-Glaninger A, Finsterer J. Dependency of phenprocoumon dosage on polymorphisms in the VKORC1 and CYP2C9 genes. J Thromb Haemost 2009; 28:211-214
24. Ufer M. Comparative pharmacokinetics of vitamin K antagonists. Clin Pharmacokinet 2005; 44:1227-1246
25. Beinema M, Brouwers JB, Schalekamp T, Wilffert B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost 2008; 100:1052-1057
26. Stehle S, Kirchheiner J, Lazar A, Fuhr U. Pharmacogenetics of oral anticoagulants. A basis for dose individualization. Clin Pharmacokinet 2008; 47:565-594
27. Sontag TP, Parker RS. Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism: novel mechanism of regulation of vitamin E status'. J Biol Chem 2002; 277:25290-25296
28. Visser L, Trienekens P, De Smet P, Vulto A, Hofman A, Van Duijn C, et al. Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants. Pharmacogenet Genomics 2005; 15:69-74
29. Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, Rebbeck TR. Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen 2003; 42:299-305
30. Hofman A, Grobbee DE, De Jong PT, Van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991; 7:403-422
31. Hofman A, Breteler MMB, Van Duijn CM, Krestin GP, Pols HA, Stricker BHCh, et al. The Rotterdam Study: objectives and design update. Eur J Epidemiol 2007; 22:819-829
32. Hofman A, Breteler M, Van Duijn C, Janssen H, Krestin G, Kuipers E, et al. The Rotterdam Study: 2010 objectives and design update. Eur J Epidemiol 2009; 24:553-572
33. Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marciante KD, et al. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat Genet 2010; 42:45-52
34. Li Y, Abecasis G. Rapid haplotype reconstruction and missing genotype inference. Am J Hum Genet 2006; S79:2290
35. International HapMap Consortium. The International HapMap Project. Nature 2003; 426:789-796
36. Flockhart DA, O'Kane D, Williams MS, Watson MS, Flockhart DA, Gage B; ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med 2008; 10:139-150
37. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352:2285-2293
38. Pe'er I, Yelensky R, Altshuler D, Daly MJ. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. Gen Epidemiol 2008; 32:381-385
39. Aulchenko Y, Struchalin M. ProbABEL manual. http://mgabionetnscru/ Byurii/ABEL/manualpdf 2009; visited on 5 March 2010
40. The Human Gene Compendium. GeneCards. http://wwwgenecardsorg/ cgi-bin/carddisppl?gene = Shc3 visited 3 August 2010
41. Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. The Lancet 1999; 353:717-719
42. Schalekamp T, Brassé BP, Roijers JFM, Chahid Y, Van Geest-Daalderop JHH, De Vries-Goldschmeding H, et al. VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther 2006; 80:13-22
43. McDonald MG, Rieder MJ, Nakano M, Hsia CH, Rettie AE. CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant, Mol Pharmacol 2009; 75:1337-1346. [Epub 18 March 2009]. p. mol.109.054833
44. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, Gardina P, et al. CYP4F2 genetic variant alters required warfarin dose. Blood 2008; 111:4106-4112
45. Lee S-J, Goldstein JA. Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests. Pharmacogenomics 2005; 6:357-371
46. Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJR, Bumpstead S, et al. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009; 113:784-792
47. Van Schie RMF, Wadelius M, Kamali F, Daly AK, Manolopoulos VG, De Boer A, et al. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 2009; 10:1687-1695